Multicenter experience of using Fortelyzin during staged reperfusion therapy of acute ischemic stroke in anterior circulation

To evaluate the safety and efficacy of Fortelyzin in the performance of staged reperfusion therapy for acute ischemic stroke (intravenous thrombolytic therapy plus mechanical thrombectomy) in anterior circulation within the FORTA RF multicenter pilot study. The study included 72 patients with acute...

Full description

Saved in:

Bibliographic Details
Published in:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Vol. 123; no. 6; p. 72
Main Authors:	Volodyukhin, M Yu, Khasanova, D R, Timchenko, L V, Podshivalov, I A, Telyatnik, Yu A, Demin, T V, Zagidullin, B I, Mukhamadieva, Y S, Mingazetdinov, M A, Yusupov, R I, Sinutin, V N
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2023
Subjects:	Administration, Intravenous Humans Ischemic Stroke Pilot Projects Reperfusion Tissue Plasminogen Activator thrombolysis Fortelyzin thrombectomy ischemic stroke
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To evaluate the safety and efficacy of Fortelyzin in the performance of staged reperfusion therapy for acute ischemic stroke (intravenous thrombolytic therapy plus mechanical thrombectomy) in anterior circulation within the FORTA RF multicenter pilot study. The study included 72 patients with acute ischemic stroke in anterior circulation, who underwent staged reperfusion therapy in four vascular centers of the Russian Federation from December 2019 to January 2023. The mean time from illness onset to hospitalization was 94.5 minutes in the Fortelyzin group and 97.2 min in the Actilyse group ( =0.78). The time from the moment of hospitalization to the admission of the patient to the X-ray operating room was significantly lower in the Fortelyzin group ( =0.002). The incidence of symptomatic hemorrhagic transformations in the Fortelyzin group was 6%, in the Actilyse group - 8% ( =0.75). A favorable functional outcome in the first group was observed in 47% of patients, in the control group in 42% ( =0.66). Mortality in both groups did not differ significantly and amounted to 22% and 25%, respectively. The first results of the FORTA RF multicenter study demonstrate the safety and efficacy of Fortelyzin in staged reperfusion therapy compared to Actilyse.
ISSN:	1997-7298
DOI:	10.17116/jnevro202312306172